Esteu aquí: Inici > Més notícies > The effectiveness of a new drug against malaria has been proved using synchrotron light

Notícia

Compartir Share

The research may contribute to the development of more effective drugs against malaria

The effectiveness of a new drug against malaria has been proved using synchrotron light

Researchers from the Universitat Politècnica de Catalunya · BarcelonaTech (UPC), the Instituto de Química Mèdica (IQM-CSIC) and the University of Glasgow have proved that the CD27 drug is a true alternative against malaria. They have analysed the crystalline structure of the DNA with the drug by performing X-ray diffraction experiments at the ALBA synchrotron.

21/07/2014
href="https://saladepremsa2.upc.edu/en"href="https://saladepremsa2.upc.edu/en"href="https://saladepremsa2.upc.edu/en"">ALBA synchrotron. X-rays, when they pass through the crystal and diffract, project images of spots which, after mathematic analysis, can solve the tridimensional structure of a molecule. When MACROM researchers solved the 3D structure, they identified the details of CD27’s structure, enabling the drug to recognise the regions of DNA covering the minor groove and preventing the development of the parasite. At the same time, these studies contribute to a rational design of new drugs, bearing in mind the molecular interactions caused by CD27.

Results of this research have been validated and deposited at the Protein Data Bank, a 3D database of proteins and nucleic acids, and published in the journal Acta Crystallographica D. The drug is patent-free and can be produced by any pharmaceutical company interested in its development.

Malaria, responsible for more than one million deaths every year
Malaria is an infectious disease caused by a parasite of the Plasmodium genus that is transmitted by a mosquito bite. It deeply affects African countries, although it is also present in some areas of Latin America and Asia (with an estimated at-risk population of 3.4 billion, according to the World Health Organization). It is thought that malaria causes more than one million deaths every year and the parasite’s resistance to existing drugs is an obstacle in the treatment of the disease.

The ALBA synchrotron
ALBA is the Spanish synchrotron light source. It is a complex of electron accelerators that produce synchrotron light, which allows the atomic structure of matter to be visualised and its properties to be studied. ALBA has been in operation since May 2012 and has seven experimental beamlines.

This scientific infrastructure produces 5,000 hours of beamtime per year and is available for academics and the industrial sector and serves more than 1,000 researchers every year.


Segueix-nos a Twitter Obriu l'enllaç en una finestra nova
És notícia
Kip S. Thorne, investit doctor 'honoris causa' per la UPC Kip S. Thorne, doctor ‘honoris causa’ per la UPC, distingit amb el Premi Nobel de Física L’astrofísic nord-americà Kip S. Thorne, doctor ‘honoris causa’ per la Universitat ... [llegir +]
La tecnologia aeroespacial del futur, aquest dissabte al CosmoCaixa La UPC i CosmoCaixa organitzen ‘Moonit’ per descobrir la tecnologia aeroespacial del futur El proper dissabte, 7 d’octubre, de 19 a 24 hores, tindrà lloc al CosmoCaixa de Barcelona la Nit ... [llegir +]
El dispositiu sense fil WOMEN-UP que es mostra a l'IOThings Solutions World Congress. Tecnologia avançada de la UPC, a l’IOT Solutions World Congress La Universitat Politècnica de Catalunya (UPC) donarà a conèixer solucions avançades en ... [llegir +]
Amb la col·laboració de:
Fundació Espanyola per a la Ciència i la Tecnologia Any de la Ciència 2007 Ministerio de Ciencia e Innovación
Aquest web utilitza cookies pròpies per oferir una millor experiència i servei. En continuar amb la navegació entenem que acceptes la nostra política de cookies Obriu l'enllaç en una finestra nova.
Oficina de Mitjans de Comunicació.
C/ Jordi Girona 31, 08034 Barcelona Tel.: +34 93 401 61 43
oficina.mitjans.comunicacio@(upc.edu)
© UPC Obriu l'enllaç en una finestra nova. Universitat Politècnica de Catalunya · BarcelonaTech